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As sequencing technology improves, the identiﬁcation of new disease-associated genes
and new alleles of known genes is rapidly increasing our understanding of the genetic
underpinnings of rare diseases, including neuromuscular diseases. However, precisely
because these disorders are rare and often heterogeneous, they are difﬁcult to study in
patient populations. In parallel, our ability to engineer the genomes of model organisms,
such as mice or rats, has gotten increasingly efﬁcient through techniques such as CRISPR/
Cas9 genome editing, allowing the creation of precision human disease models. Such in
vivo model systems provide an efﬁcient means for exploring disease mechanisms and
identifying therapeutic strategies. Furthermore, animal models provide a platform for
preclinical studies to test the efﬁcacy of those strategies. Determining whether the
same mechanisms are involved in the human disease and conﬁrming relevant
parameters for treatment ideally involves a human experimental system. One system
currently being used is induced pluripotent stem cells (iPSCs), which can then be
differentiated into the relevant cell type(s) for in vitro conﬁrmation of disease
mechanisms and variables such as target engagement. Here we provide a
demonstration of these approaches using the example of tRNA-synthetase-associated
inherited peripheral neuropathies, rare forms of Charcot-Marie-Tooth disease (CMT).
Mouse models have led to a better understanding of both the genetic and cellular
mechanisms underlying the disease. To determine if the mechanisms are similar in
human cells, we will use genetically engineered iPSC-based models. This will allow
comparisons of different CMT-associated GARS alleles in the same genetic
background, reducing the variability found between patient samples and simplifying the
availability of cell-based models for a rare disease. The necessity of integrating mouse and
human models, strategies for accomplishing this integration, and the challenges of doing it
at scale are discussed using recently published work detailing the cellular mechanisms
underlying GARS-associated CMT as a framework.
Keywords: rare disease, charcot-marie-tooth disease, motor and sensory neuropathy, mouse model, iPSC model
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INTRODUCTION

generate cell lines carrying multiple pathogenic GARS alleles.
Alternatively, even if the mechanisms and targets are shared, the
therapeutic tested in animals may not be equally effective in
humans due to differences between mouse and human genetics,
metabolism, or development. To address these issues and thus
improve the translational potential of animal studies, it becomes
necessary to also have a human experimental system. Induced
pluripotent stem cells [iPSCs, (Takahashi et al., 2007)] potentially
provide such a system, particularly as they can be derived directly
from patients, or alternatively, speciﬁc patient mutations can be
engineered into existing “healthy control” cell lines. In addition,
iPSCs can be differentiated into many cell types of interest, such
as motor neurons or cortical neurons, so that one is not restricted
to studying neurodegeneration in skin ﬁbroblasts or lymphocytes,
for example. However, cell-based models also have inherent
limitations, including the relative immaturity of their postdifferentiation states, the comparatively isolated nature of the
cell compared to their in vivo milieu, and the inevitable
abstraction of the disease to a cellular phenotype (Santoso and
Mccain, 2020). For example, patients do not see a neurologist
because of reduced axonal transport, they go because of weakness
or sensory deﬁcits in their feet or hands, and whether improving
axonal transport is truly tantamount to improving sensory/motor
function in vivo is often a hopeful assumption.
We propose a solution to address the limitations of both animal
models and cell-based models in which the ﬁndings in each are
integrated to provide the best chance for successful translation of
experimental approaches into clinical application. Here we will use
the example of forms of Charcot-Marie-Tooth disease (CMT) to
demonstrate how animal models have led to a better understanding
of these diseases and have identiﬁed therapeutic targets and
strategies that have been validated in vivo. We will also describe
our strategy for using engineered human cell-based models to test
whether the same pathogenic mechanisms and therapeutic strategies
translate to a human system.

The number of disease-associated genes and pathogenic variants in
those genes is rapidly increasing through the efforts of large-scale
discovery programs such as the Centers for Mendelian Genomics
(Posey et al., 2019). According to numbers from the World Health
Organization, there are now as many as 8,000 rare diseases, many of
which are genetic, and in aggregate, these disorders affect ∼1 in 15
people. However, there is no treatment for ∼90% of these disorders.
With this increased rate of discovery and ongoing unmet clinical
need comes the challenge of understanding how a given mutation
leads to a given disease or phenotype. In some cases, this may be
clear from the known function of the mutated gene, but more
frequently, it requires a detailed exploration of the underlying
genetic, cellular, and molecular mechanisms. Accomplishing such
studies in patient populations is challenging for both ethical and
practical reasons. It is even more challenging in the case of rare
diseases, where access to patients is difﬁcult and research materials
such as surgical discards or postmortem samples are not available or
are too rare to provide an experimentally feasible approach. In such
cases, animal models can be powerful tools for in vivo
experimentation. Animals can be used in sufﬁcient numbers to
provide well-powered studies and are more amenable to experiments
that cannot be performed in humans. Furthermore, these animal
models can be used to identify possible therapeutic strategies based
on the identiﬁed disease mechanism, and to test these strategies in
preclinical studies.
However, translation from animal models to patients is not
always successful. Notable examples of this in neuroscience and
neurology are failures to translate ﬁndings in animal models of
amyotrophic lateral sclerosis (ALS) or Alzheimer’s Disease into
successful clinical trials (Drummond and Wisniewski, 2017;
Perrin, 2014; Philips and Rothstein, 2015). Sometimes this
may reﬂect limitations of the model, such as when it does not
fully recapitulate the human pathophysiology; for instance, a
mouse model of CMT type 2D (CMT2D; GarsC201R) develops a
neuropathy with smaller axons, decreased nerve conduction
velocity, grip strength, and body weight, but does not have
frank axon loss. Due to the lack of axon degeneration, this
would not be a good mouse model for testing therapies aimed
at preventing axon loss, such as SARM1 inhibitors (Moss and
Hoke, 2020). Fortunately, more severe CMT2D mouse models
that do show axon degeneration exist (Table 1), and we will

TRNA SYNTHETASE-ASSOCIATED FORMS
OF CHARCOT-MARIE-TOOTH DISEASE
The clinical hallmarks of CMT include degeneration and
dysfunction in motor and sensory axons in the peripheral
nervous system, leading to a length-dependent loss of

TABLE 1 | Current mouse models of Gars/CMT2D.
Mutation
C201R
ΔETAQ
P278KY
G240R
L129P

Method of mutagenesis

Severity

ENU-induced
CRISPR knock-in
Spontaneous
Adenovirus overexpression
Adenovirus overexpression

Mild
Severe
Severe
Moderate
Pain

Original publication
Achilli et al., Dis Model Mech., 2009
Morelli et al., J Clin Invest., 2018
Seburn et al., Neuron, 2006
Seo et al., J Mol Histol., 2014
Seo et al., J Korean Med Soc., 2014

Table 1 The C201R allele is not found in patients. While it causes marked weakness and reduced nerve conduction velocity, it has very little axon loss in motor or sensory nerves. The
ΔETAQ allele is a mouse model recreating a de novo human mutation. It has a severe phenotype and pronounced axon loss in motor and sensory axons beginning at a few weeks of age.
The P278KY allele is also not found in patients. It has a phenotype slightly more severe than ΔETAQ and can lead to premature mortality in an inbred genetic background. All three
mutations are dominant and lead to a similar activation of the integrated stress response. The G240R and L129P mouse models were generated by viral overexpression of the mutant
proteins. This has the advantage of efﬁciently testing pathogenicity for potential gain-of-function or dominant-negative alleles, but axonopathy was not characterized in these models.
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exceptions, such as GARSE71G and YARSE196K, which retain
most of their enzymatic activity in in vitro assays; however,
loss of function in vivo could also result from mechanisms
such as protein instability or mislocalization (Jordanova et al.,
2006; Nangle et al., 2007).
However, data also argue against a simple loss of function and
instead suggest a toxic gain-of-function (neomorphic)
mechanism, in which the mutant gene product takes on a
new, toxic function that cannot be corrected or out competed
by the wild type gene product. First, in both humans and mice, a
heterozygous null allele of GARS does not have a phenotype,
indicating the neuropathy is not the result of a simple
haploinsufﬁciency (Seburn et al., 2006; Oprescu et al., 2017).
Furthermore, patients with recessive partial-loss-of-function
mutations have severe, multisystem syndromic disorders in
which peripheral neuropathy is not a prominent feature. If the
dominant mutations led to peripheral neuropathy through a lossof-function mechanism and thus served as a bellwether of
dysfunction, then presumably these more severe recessive
syndromes would also include peripheral neuropathy as an
early and severe outcome. However, perhaps the most
convincing data supporting a neomorphic activity comes from
animal models. In Drosophila, the transgenic overexpression of
mutant GARS or YARS leads to axon degeneration and CMTrelevant phenotypes, whereas overexpression of the wild-type
genes has no effect, and the endogenous ﬂy Gars and Yars are still
functional (Storkebaum et al., 2009; Grice et al., 2015; Niehues
et al., 2015). Indeed, levels of tRNA charging activity in tissue
homogenates were never reduced below wild-type levels, arguing
against a dominant negative effect leading to loss of function
(Niehues et al., 2015). In a reciprocal experiment in mice,
transgenic overexpression of wild-type GARS did not rescue
the neuropathy phenotype of dominant Gars mutations
(Motley et al., 2011). The failure of robust overexpression of
the wild-type protein to rescue is most consistent with a
neomorphic activity, whereas a loss of function or even
dominant negative should be at least partially corrected by
excess wild-type expression.
Conﬁrming the genetic mechanism is critical for designing
gene therapies, such as gene replacement or gene knockdown. As
an example in neuromuscular diseases, spinal muscular atrophy
can be treated by delivery of the wild-type SMN1 gene by AAV9mediated delivery to motor neurons (Mendell et al., 2017). This is
now an approved therapeutic approach for SMA. A similar gene
replacement strategy was shown to be effective in a mouse model
of CMT type 4J, caused by recessive mutations in Fig4 (Presa
et al., 2021). However, the Gars transgenic mouse result showing
that transgenic overexpression of the wild-type gene does not
correct the phenotype argues against a gene replacement
approach for GARS/CMT2D. Instead, the fact that
heterozygous null mice and human carriers are healthy
suggests that allele-speciﬁc knockdown of the mutant gene
product while preserving the expression of the wild type allele
should be an effective strategy. If done with complete efﬁciency
and speciﬁcity, this strategy would effectively reproduce the
heterozygous null situation and eliminate any neomorphic
effect of the mutant protein.

sensation and muscle strength that is most pronounced in the feet
and hands (Saporta and Shy, 2013). Mutations in close to 100
genes are now associated with CMT, suggesting a diverse array of
mechanisms that can lead to a similar condition clinically
(Timmerman et al., 2014; Laura et al., 2019). The largest gene
family associated with CMT is the amino-acyl tRNA synthetase
(aaRS) family, with dominant mutations in as many as six aaRS
genes leading to forms of CMT (Wei et al., 2019). The ﬁrst to be
identiﬁed was Glycyl-tRNA synthetase (GARS), as the cause of
CMT2D (Antonellis et al., 2003). Since that discovery in 2003,
dominant mutations in Tyrosyl- (YARS), Alanyl- (AARS),
Histidyl- (HARS), Tryptophanyl- (WARS), and possibly
methionyl- (MARS) tRNA synthetases have been associated
with forms of CMT (Jordanova et al., 2006; Latour et al., 2010;
Gonzalez et al., 2013; Vester et al., 2013; Tsai et al., 2017). Most of
these mutations lead to axonal forms of CMT, in which the motor
and sensory axons themselves degenerate, without obvious
involvement of the peripheral myelinating Schwann cells.
However, mutations in YARS lead to an “intermediate” form
of CMT (dominant intermediate CMT type C/diCMTC), with
moderately reduced nerve conduction velocities, suggesting
demyelination. Like many forms of CMT, the age of onset and
severity vary both with gene and with the allele. For example,
mutations in GARS/CMT2D patients may be incompletely
penetrant, or lead to exclusively motor neuropathy, even in
patients carrying the same allele (L129P) (Sivakumar et al.,
2005). In contrast, at least one GARS patient was ascertained
at 13 months of age with severe motor neuropathy resembling
spinal muscular atrophy (Morelli et al., 2019). GARS/CMT2D
patients are also distinctive in that they often have more severe
symptoms in their hands than in their feet, whereas most forms of
CMT are more severe in the lower extremities (Antonellis et al.,
2003). Despite these idiosyncrasies, the neuropathies resulting
from dominant tRNA synthetase mutations generally ﬁt the
clinical criteria for CMT.
How mutations in these genes lead to neuropathy was initially
unclear. A primary question is whether the mutations cause a
gain- or loss-of-function in the mutant protein? A second
question is why the disease is speciﬁc to motor and sensory
neurons, since the genes are expressed ubiquitously and involved
in the “housekeeping” function of charging amino acids onto
their cognate tRNAs as the ﬁrst step in translation? We will
summarize progress on the ﬁrst point, as the genetic, cellular and
molecular underpinnings of these disorders are becoming clearer,
even if the second point of cellular speciﬁcity remains puzzling.

GENETIC MECHANISMS INFORM GENE
THERAPY STRATEGIES
Many of the dominant mutations in tRNA synthetase genes that
cause peripheral neuropathy also cause a reduction or loss of the
mutant enzyme’s tRNA charging activity (Grifﬁn et al., 2014).
Furthermore, these enzymes form homodimers, and this is
necessary for activity, leading to the possibility that there
could be dominant negative effects in which the mutant
subunit poisons the activity of the dimer. There are notable
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This was indeed shown to be an effective strategy in mouse
models (Morelli et al., 2019). Two alleles of Gars, including one
carrying an engineered human disease-associated allele, were
treated with allele-speciﬁc RNAis that precisely matched the
mutant allele but mismatched with the wild-type mRNA. The
RNAi was generated from an engineered mir30 microRNA
shuttle that was expressed behind an RNA PolIII U6
promoter. This was delivered to the nervous system in vivo
using self-complementary AAV9. When delivered at birth,
2–3 weeks before the onset of a neuropathy phenotype, the
disease was almost completely prevented, and consistent with
the perdurance of expression from AAVs, beneﬁcial effects lasted
at least 1 year. Beneﬁt was still obtained with delivery after the
onset of neuropathy, but decreased the later treatment was
started. Whether the declining efﬁcacy is because the
phenotype is irreversible or whether it is because AAV9
spread and transduction efﬁciency decreases with age is unclear.
The preclinical gene therapy studies described above provide
the in vivo proof-of-concept conﬁrmation that eliminating the
mutant gene product produces clinical beneﬁt. It is likely that
similar effects could be produced with other approaches, such as
allele-speciﬁc antisense oligonucleotides. However, target
sequence-speciﬁc strategies require extensive research and
development and regulatory efforts for each new sequence
entity. An alternative approach that may provide a “generic”
strategy for any GARS mutation (or any dominant neomorphic
mutation) is to knockdown all transcripts, mutant and wild type,
and to replace them with a knockdown-resistant wild-type
cDNA, ideally delivered in the same vector as the knockdown
RNAi so that any cell getting the knockdown also gets the
replacement. Such a strategy has been successfully executed in
mice for alpha-1 antitrypsin (Li et al., 2011), and is being explored
for GARS/CMT2D.

in CMT patients (NCT04980807). Improving synaptic
transmission at the NMJ is unlikely to address the core
pathophysiology of these disorders and would therefore not
necessarily be expected to slow progression or promote
regeneration. However, it may improve function for patients
who already have the disease, and a further exploration of
NMJ involvement in different forms of CMT is warranted in
both mouse models and patients.
Investigations of the neomorphic activities of mutant tRNA
synthetases have focused on novel interactions mediated by the
mutant protein that are not found in the wild-type protein.
Mutations in both GARS and YARS (also known as GlyRS and
TyrRS for proteins) result in conformational changes that
potentially expose new protein surfaces, enabling novel
interactions (Nangle et al., 2007; Xie et al., 2007; Blocquel
et al., 2017). One intriguing interaction identiﬁed is the
binding of Neuropilin-1 (NRP1) to mutant GlyRS (He et al.,
2015). NRP1 is a developmental receptor that has both
semaphorins and vascular endothelial growth factors (VEGFs)
as ligands. Both semaphorin and VEGF signaling have
neurodevelopmental roles, but the binding of mutant GlyRS
speciﬁcally competes with VEGF. VEGF overexpression
mitigates some aspects of the neuropathy seen in Gars mutant
mice. The necessity of GlyRS binding NRP1 for the disease
mechanism leading to neuropathy is called into question by
the failure of NRP1 to bind ΔETAQ, a four amino acid
internal deletion in GlyRS that causes a severe, early onset
neuropathy in both mice and humans (Morelli et al., 2019).
Nonetheless, several other neuropathy-associated mutant GlyRS
proteins bind NRP1, as do CMT2N-associated alleles of AARS,
suggesting that it may in some way be contributing to the disease
severity and pathogenesis (He et al., 2015; Sun et al., 2021). This
also suggests that small molecules to block this interaction or
antibodies to clear mutant GlyRS proteins could be therapeutic
strategies.
Recent results suggest an alternative biochemical mechanism
that may extend more logically across the tRNA synthetaseassociated neuropathies (Figure 1). The mutant forms of
GlyRS and TyrRS bind their cognate tRNAs, but have a much
slower off-rate, effectively resulting in the sequestration of the
tRNAs and precluding their transfer to the ribosome to
participate in translation. Consistent with tRNA sequestration
being considered a toxic, gain-of-function activity,
overexpression of mutant forms of GARS in HEK293 cells
resulted in ribosome stalling at Glycine codons, as expected if
the mutant enzymes were expressed at high enough levels to
sequester tRNAs in cell types where the tRNAs are not typically
limiting (Mendonsa et al., 2021). In addition to these biochemical
ﬁndings, this mechanism is also supported genetically for GARS.
The overexpression of tRNAGly rescues neuropathy and axon
degeneration phenotypes in both mouse and ﬂy models of GARS/
CMT2D (Zuko et al., 2021). This is in contrast to overexpression
of the wild-type synthetase in mice (Motley et al., 2011), which
despite being active does not rescue, and would have a paucity of
tRNA substrate to charge under this mechanistic model.
The result of tRNA sequestration is stalling of elongating
ribosomes at Glycine codons. Stalled ribosomes are potent

CELLULAR AND BIOCHEMICAL
MECHANISMS SUGGEST THERAPEUTIC
STRATEGIES
Axonal peripheral neuropathies are generally considered to be
problems of axon degeneration and clearly axon degeneration
disconnects neurons from their targets, whether these are sensory
endings in the periphery, or muscles in the case of motor neurons.
However, in Gars/CMT2D mouse models, it was also shown that
while axons maintained neuromuscular junctions (NMJ), but had
perturbed synaptic morphology and function at the NMJ
(Spaulding et al., 2016). In fact, this was true even in proximal
muscles that had little frank denervation. Therefore, part of the
neuromuscular phenotype of these mice could be considered a
myasthenia and not just an axonal neuropathy. This raises the
possibility that therapeutics designed to enhance synaptic
transmission at the NMJ may be beneﬁcial in CMT2D.
Whether defects in NMJ transmission are commonplace in
other axonal neuropathies remains to be tested, but it stands
to reason that the axons that remain intact in these diseases may
not be functioning perfectly, and that this would manifest itself at
the NMJ. This possibility is now being explored in a clinical trial
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FIGURE 1 | tRNA sequestration by mutant tRNA synthetases. (A) In normal tRNA charging, the amino acid binds the tRNA synthetase and is coupled with ATP to
form an aminoadenylate intermediate. The amino acid is then charged onto the 3′ end of the cognate tRNA. The amino acid-charged tRNA is shuttled to the ribosome by
eEF1A to participate in translation. (B) Mutant tRNA synthetases do not release the tRNAs to eEF1A, thus resulting in a paucity of charged tRNAs for translation
elongation and subsequently ribosome stalling at Glycine codons (in the case of mutant glycyl tRNA-synthetase). The stalled ribosomes activate GCN2 and the
integrated stress response, resulting in a suppression of global cap-dependent translation through eIF2α phosphorylation, and activation of ATF4 target gene
expression.

Frontiers in Cell and Developmental Biology | www.frontiersin.org

5

January 2022 | Volume 9 | Article 801819

Hines et al.

Models of Inherited Peripheral Neuropathy

activators of the kinase GCN2 and subsequently, the integrated
stress response (ISR) (Inglis et al., 2019). Interestingly,
mitochondrial dysfunction is also an ISR activator, and GlyRS
is a bifunctional enzyme that also encodes the mitochondrial
glycyl-tRNA synthetase (Turner et al., 2000). In fact, patients with
recessive loss-of-function GARS mutations experience a
multisystem developmental syndrome with mitochondrial
abnormalities (Mcmillan et al., 2014; Oprescu et al., 2017).
While mitochondrial dysfunction has not been explicitly ruled
out as an activator of the ISR in mouse models of CMT2D, the
fact that TyrRS (and all of the other known CMT-associated
synthetases, AlaRS, HisRS, MetRS, and TrpRS) is cytosolic and
not mitochondrial, yet CMT-associated YARS mutations in mice
and humans cause a similar phenotype, argues against
mitochondrial involvement as the primary disease mechanism.
The ISR is beneﬁcial under many forms of cellular stress
(Pakos-Zebrucka et al., 2016). For example, amino acid
starvation also causes uncharged tRNA and stalled ribosomes,
both of which activate GCN2. The result is the phosphorylation of
elongation initiation factor 2-alpha (eIF2α). This globally
suppresses cap-dependent translation. In addition, the
translation of the stress-response transcription factor, ATF4, is
increased through an upstream open reading frame mechanism
that regulates its synthesis (Vattem and Wek, 2004). ATF4
promotes the expression of cell-type-speciﬁc stress response
genes. Thus, by suppressing cap-dependent translation and
enhancing expression of stress response genes, the ISR can be
beneﬁcial in the face of a transient stress such as amino acid
starvation.
Importantly, in tRNA synthetase-associated CMTs, the ISR is
not being activated by a transient stress, but instead by the
chronic sequestration of tRNAs. In an analogous case of
neurodegeneration caused by ribosome stalling during
translation elongation due to a combination of a tRNAAla
mutation and loss of GTPBP2, which rescues stalled ribosomes
from mRNAs, the inhibition of GCN2 and the ISR is detrimental,
exacerbating the associated neurodegeneration (Ishimura et al.,
2014; Ishimura et al., 2016). However, in the case of Gars/CMT2D
mouse models, genetically deleting or pharmacologically
inhibiting GCN2 not only eliminates ISR activation, but also
greatly mitigates the severity of the neuropathy phenotype
(Spaulding et al., 2021). That an experimental drug was also
effective in mitigating neuropathy in the Gars mice speaks to the
translational potential of inhibiting GCN2 to treat dominant
tRNA synthetase-associated peripheral neuropathies.
Although these studies provide a biochemical mechanism
through which tRNA synthetase mutations may act and
identify GCN2 as a therapeutic target, they do not directly
resolve whether the neuropathy results from the further
decrease in protein synthesis that results from phosphorylation
of eIF2α, from a toxic effect of ATF4 target-gene expression, or
from a combination of these ISR actions. Nor does this
biochemical mechanism explain the cell-type speciﬁcity of the
disease and why only alpha motor neurons and a subset of
sensory neurons are affected. The ﬁnding that the ISR is
similarly activated in both Gars and Yars mutant mice
suggests that this mechanism may be in play across the tRNA
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synthetase-associated neuropathies, though this remains to be
tested for mutations in HARS, WARS and AARS. Furthermore,
though the Gars/CMT2D mouse models accurately recapitulate
the human disease, it also remains to be determined whether the
same ISR mechanism is active in human motor and sensory
neurons. Circulating levels of one prominently upregulated,
secreted ATF4 target gene, GDF15, were elevated in patients
with tRNA synthetase mutations; however, GDF15 was also
elevated in PMP22/CMT1A patients (Spaulding et al., 2021).
This is interesting and may suggest GDF15 is a general
biomarker for multiple forms of CMT, but it makes the direct
relevance to ISR activation in the tRNA synthetase mutations less
deﬁnitive. Conﬁrming activation of the ISR and further exploring
the biochemical mechanisms and cellular speciﬁcity of the disease
are all questions that can be efﬁciently addressed using human
cell-based models.

HUMAN CELL-BASED MODELS OF TRNA
SYNTHETASE-ASSOCIATED
NEUROPATHY
Rare diseases present a challenge for iPSC derivation and
experimentation. Namely, patients are challenging to ﬁnd and
generating an experimentally robust battery of patient-derived
cell lines accounting for multiple genes and multiple alleles of
each gene, as well as other biological variables such as sex, age,
and ethnicity may simply not be feasible. Other technical
variables, such as the cell type from which the iPSCs were
derived, the protocol for reprogramming those cells, and the
culture conditions may all create additional complications,
particularly if cell lines are being sourced globally and are not
being generated through a centralized facility or research
program. While there are large research programs attempting
to overcome these challenges by increasing the number of control
and mutant cell lines being compared, such as AnswerALS
(https://www.answerals.org/), for most laboratories, it would
quickly lead to even the simplest experiments becoming
unwieldy.
One possible solution to these practical and technical
challenges is to use engineered cell-based models. Efﬁcient
genome editing in human cell lines makes the introduction of
most human disease-associated mutations in a “healthy control”
iPSC line relatively straightforward (Figure 2). For rigor, these
mutations can be introduced into multiple cell lines to begin to
capture human genetic diversity. Cell-based models can also be
engineered so that they can be reverted, such that both the
parental cell line and the revertant can serve as controls for
the mutated cell line. The use of revertant cells is most important
when the pathogenicity of the allele is uncertain, or if only a single
pathogenic variant is known or available, as is sometimes the case
for rare diseases. For patient-derived cells, revertant cells would
control for genetic background by ﬁxing the causative mutation.
In the engineered cells, revertant lines serve as a stringent control
for the targeting and gene editing process required to introduce
the mutation. The use of revertant strains may be unnecessary if a
large number of independent disease-associated and healthy
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FIGURE 2 | Schematic for modeling rare neuromuscular disorders using genetically engineered iPSCs. (A) KOLF2 iPSCs genetically engineered to carry CMTassociated GARS mutations can be differentiated into motor neurons, which are affected by CMT, and cortical neurons, which are not affected by CMT. The wild-type
parental cells and revertant cells (which have had the introduced GARS mutation corrected back to WT) can be used as controls. (B) Translation assays, high content
imaging and morphometrics, and gene expression analysis can be used to determine if the ISR is activated in GARS mutant motor neurons. (C) If motor neurons
have the expected phenotype (ISR induction), then they can be used for further mechanistic experiments, such as ribosome stalling assays and analysis of biochemical
properties of tRNA sequestration. These cells can also be used for high-throughput screens of therapeutics.

exploring disease mechanisms (Figure 2). In the case of
GARS/CMT2D, the human disease is a predominantly motor
neuropathy, and there are no reproducible pleiotropic effects. In
mouse models, the activation of the integrated stress response is
speciﬁc to alpha motor neurons and a subset of sensory neurons,
and presumably this indicates that ribosome stalling is restricted
to these cell types. Consistent with this, when the ribosome rescue
factor Gtpbp2 was genetically deleted, the neuropathy phenotype
of Gars mice become more severe, providing indirect genetic
evidence for ribosome stalling; however, the ISR did not appear in
other cell types even after the ribosome rescue factor was deleted
(Zuko et al., 2021).
This speciﬁcity of ribosome stalling presents a challenge for
detailed studies of this mechanism in vivo. Motor neurons
represent a small fraction of the total cells in the spinal cord,
and ribosomes isolated from bulk tissue complicate interpretation
of assays such as ribosome footprinting, in which RNase digestion
removes mRNA except those regions protected by a stalled
ribosome. Such assays could identify particular mRNAs or
particular Glycine codons that are particularly sensitive to
ribosome stalling in motor neurons. The latter may identify

control cell lines are available. In such a case, rigor is provided by
consistency across independent cell lines and the use of revertant
cell lines could again make the approach unwieldy.
Another advantage of the engineered cell lines is that multiple,
related mutations can be introduced independently into the same
cell line. Thus, cell-based models, each carrying a diseaseassociated allele of GARS, for example, can be generated and
compared to otherwise isogenic lines carrying mutations in other
tRNA synthetase genes such as YARS, AARS, WARS or HARS.
Much like engineering disease models in a single inbred mouse
strain allows for consistency and an “apples-to-apples”
comparison of phenotypes and mechanisms, these cell-based
models should vary only in their disease-associated mutation
or allele that they carry. This approach of introducing diseaseassociated variants into a well-deﬁned cell line is being used to
study genes and variants associated with Alzheimer’s and related
dementias, through the iPSC Neurodegenerative Disease
Initiative (iNDI) program, for example (Ramos et al., 2021).
In addition to the obvious advantage of demonstrating the
same pathophysiological mechanisms are engaged in a human
disease model, iPSC-based models also have advantages for
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speciﬁc anticodon tRNAs that are most limiting after
sequestration by the mutant synthetase. Since iPSCs can be
differentiated to motor neurons with high efﬁciency, resulting
in a relatively homogeneous population of cells, experiments such
as ribosome footprinting will be much more straightforward in
cell-based models, where ribosomes can be rapidly isolated from
the bulk culture. It is even possible to generate speciﬁc subpopulations of motor neurons, such as cranial motor neurons, or
limb-innervating lateral motor column motor neurons (Amoroso
et al., 2013; An et al., 2019). This is additional degree of
differentiation is potentially useful given that CMT2D
primarily affects spinal alpha motor neurons.
The homogeneity and scalability of culture systems will also be
an advantage for probing the cell-type speciﬁcity of ISR
activation. The same iPSCs can be differentiated into motor
neurons, where we expect to see ISR activation, or into a
closely related cell type, such as cortical neurons, or even an
unrelated cell type such as cardiac myocytes, where we do not
expect to see ISR activation. Thus, detailed characterization of
gene expression, codon usage, tRNA expression, and other
parameters can be performed to see if they may explain why
motor neurons exhibit ribosome stalling and ISR activation and
other cell types do not.

to extend through the grooves to form a spatially and chemically
isolated synapse on the muscle cells (Santhanam et al., 2018;
Altman et al., 2019; Ionescu and Perlson, 2019). An added beneﬁt
of this system is that treatments can be restricted to either the cell
body compartment or the axon terminal/muscle compartment if
using microﬂuidic chambers. A recently published protocol
describes the creation of an “NMJ chip”—a 3D culture system
with neurons and myocytes in separate compartments which
form functional NMJs and allows imaging and functional
assessment of the motor unit. The myocyte compartment
contains two pillars made of ﬂexible polydimethylsiloxane
(PDMS) to which the myocytes attach to form a skeletal
muscle bundle. Muscle contractile force is measured based on
the ﬂexion of the PDMS pillars (Osaki et al., 2018; Osaki et al.,
2020). One advantage of the single-well co-culture systems is that
they do not require specialized culture dishes; however, the
compartmentalized system allows for localized treatment of
axon terminals or neuronal cell bodies.
An intriguing hypothesis regarding the motor and sensory
neuron sensitivity to tRNA synthetase mutations and ribosome
stalling relates to translation in distal axons. In both mice and
humans, it is the longest and largest axons that are most affected
(Antonellis et al., 2003; Sleigh et al., 2014). Unfortunately, this
invokes many possible mechanisms. Presumably these cells are
more metabolically active to maintain their resting potential with
the large cell volume and are more dependent on efﬁcient axonal
transport to maintain their distal processes, to name just two
logical possibilities. However, they may also be more dependent
upon local protein synthesis in the distal axon to maintain
processes such as mitochondrial function that may not be
sufﬁciently supported by transport of components from the
cell body. The evidence supporting the importance of local
protein synthesis in axons is increasingly convincing (Baleriola
and Hengst, 2015; Spaulding and Burgess, 2017; Fernandopulle
et al., 2021). Axonal translation could intersect with the tRNA
sequestration mechanism described above for tRNA-synthetaseassociated neuropathies if the tRNAs become limiting, and
therefore most susceptible to sequestration, in the distal axon.
This is very challenging to test in vivo, but is straightforward to
test in vitro using compartmentalized culturing systems, which
would allow levels of both mRNAs and tRNAs in axons to be
compared to levels in cell bodies. In addition, manipulations such
as GCN2 inhibitors could be applied speciﬁcally to axons or cell
bodies to see if one compartment or the other was the primary site
of ISR activation. It is unclear how such experiments could be
done in vivo.
Thus, while caveats remain such as the maturity of the cells in
culture and whether the ISR will in fact be activated in vitro, the
iPSC cell-based models have the potential to greatly expand the
level of mechanistic studies regarding translation and ribosome
stalling. The cells also offer a rapid system for testing GCN2 and
ISR inhibitors, with cellular level readouts of ISR such as levels of
phospho-eIF2α, phospho-GCN2, or ATF4, even if frank axon
degeneration is not evident in the culture system. Importantly
though, even though the iPSC model may have also led to the
discovery of ISR activation, the in vivo animal models were
necessary to show that GCN2/ISR inhibition was an effective

ENHANCING CELL MATURITY AND
EXPLORING CELL BIOLOGICAL
MECHANISMS
While the homogeneity of an iPSC-based system can be a great
advantage for the types of studies detailed above, it may also be
beneﬁcial for us to use a co-culture system with motor neurons
and other relevant cell types. For example, human iPSC-derived
co-cultures of astrocytes and motor neurons were recently used in
a study showing that astrocytes exhibit non-cell autonomous
effects on motor neurons in an in vitro ALS model (Zhao et al.,
2020). For studies on neuromuscular disease, co-cultures of iPSCderived motor neurons with skeletal muscle cells (such as those
derived from C2C12 mouse myoblasts, primary human-derived
myoblasts, or differentiated from hiPSCs, with varying degrees of
difﬁculty and availability) to simulate a simpliﬁed version of the
neuromuscular system present in vivo, and allowing for assays of
NMJ function (Demestre et al., 2015; Picchiarelli et al., 2019; Lin
et al., 2020; Yoshioka et al., 2020; Stoklund Dittlau et al., 2021).
Furthermore, organoid culture systems allow for the
differentiation of multiple cell types to form a miniature
version and experimentally approachable model of the tissue
of interest (Vieira de Sa et al., 2021). Recently, iPSC-derived
human sensorimotor organoids, which contain motor and
sensory neurons, skeletal muscle, astrocytes, microglia, and
vasculature, have been used to assess how familial ALS
mutations affect NMJ and muscle function in vitro (Pereira
et al., 2021).
In addition to single-well co-cultures, a variety of multiple
compartmentalized culture platforms are also available. These
house the motor neurons and muscle cells in separate chambers
with microgrooves between them, which allows the motor axons
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treatment for neuropathy given that in other neurodegenerative
conditions it has been found that activation of the ISR is actually
neuroprotective (Ishimura et al., 2016; Sidoli et al., 2016). With
this knowledge, the studies in the cell-based models can be
interpreted with the sound assumption that inhibiting the ISR
in vitro should be beneﬁcial for treating neuropathy in vivo.

skeletal abnormalities, among others (Bowl et al., 2017;
Rozman et al., 2018; Swan et al., 2020). Although the KOMP2
program has focused on generating null alleles, repurposing this
capacity for more precise and/or disease-relevant alleles is quite
feasible, and would take full advantage of the engineering and
production platforms investments made to support these
programs.
Despite the potential beneﬁts of high-throughput phenotyping
for target discovery and disease gene prioritization, a signiﬁcant
phenotyping gap remains to not only make them convincing
human disease models, but also to provide the necessary
information for future mechanistic and preclinical studies.
Mechanistically, parameters such as the cell-autonomy and
tissue-speciﬁcity of the pathophysiology, or whether the
disease is developmental or degenerative need to be
determined, to name just two important considerations. For
preclinical studies, the age of onset, potential for sex-speciﬁc
differences, the most informative outcome measures, and the rate
of progression all need to be determined before any therapeutic
testing can begin. While these analyses can be pipelined to some
extent by running a standard battery of tests, each mouse model,
like each human disease, inevitably has speciﬁc characteristics
that need to be addressed, requiring a deviation from the script.
All of this requires a certain amount of bespoke analysis and
represents a somewhat slow and somewhat trial-and-error
process that reduces throughput.
Generating in vivo animal models through other technologies
such as viral delivery of mutant genes is also an option to increase
throughput. This requires the generation of many different allele
sequences and packaging these into viruses for in vivo delivery,
but these technologies are well established. Constraints on this
system are the size of constructs that can be packaged into viral
vectors, and that such overexpression systems, at least in a wildtype background, will only model gain-of-function or dominantnegative alleles. Nonetheless, this approach has been used
effectively in C9ORF72 ALS, and has been attempted for
GARS/CMT2D (Table 1), although axonopathy was not
described (Lee et al., 2014; Seo et al., 2014; Chew et al., 2015;
Herranz-Martin et al., 2017). While such viral approaches allow a
large number of alleles to be generated, phenotyping is still
required.
Cell-based models may offer greater opportunity to increase scale.
For diseases with relatively large patient populations, generating a
large and diverse patient-derived iPSC collection may be feasible.
This strategy is currently being used for sporadic forms of ALS
(SALS) by the Answer ALS Research Project, who hope to gather
and characterize iPSCs from 1000 SALS patients to ﬁnd biomarkers
of the disease, determine why motor neurons are the primary
affected cell type, and what role genetic background plays in
these sporadic cases (https://www.answerals.org/). For rarer
mutations, engineering disease-associated mutations into control
iPSC lines is feasible at reasonable scale. The iNDI program is an
example, where over 100 alleles of Alzheimer’s and related dementia
genes will be engineered into a “healthy control” iPSC line and then
phenotyped in an automated platform (Ramos et al., 2021). The
approach of engineering mutations into an otherwise isogenic
background has other potential beneﬁts, as described above.

SCALABILITY
The ﬁndings and proposed research above present a template for
studies of rare neuromuscular diseases using a combination of
animal and human cell-based models. Animal models reveal
genetic mechanisms, leading to gene therapy strategies that
can then be tested for in vivo efﬁcacy in those same models.
Similarly, animal models can reveal mechanistic insights that may
again suggest therapeutic strategies, such as the identiﬁcation of
ISR activation as a contributor to the pathophysiology and GCN2
as a drug target for GARS/CMT2D. Human cell-based models can
be used to conﬁrm those same mechanisms. They also provide a
higher throughput platform of compound testing and a more
homogeneous system for biochemistry and -omics studies, at
least compared to a cell type such as motor neurons, where the
cells of interest represent a small proportion of cells resident in
the tissue. However, this example is still incomplete, as the cellbased models are in their early stages of analysis, and it already
represents 18 years of work if the identiﬁcation of GARS as the
causative gene for CMT2D is considered the start date. In light of
this, what are the prospects for streamlining such studies and
doing them at scale?
With current technologies and infrastructure, it is feasible to
generate hundreds of genetically modiﬁed mouse strains every
year. This is exempliﬁed by large programs such as the Knockout
Mouse Phenotyping Program (KOMP2), and even small-scale
programs such as the Resource for Research on Peripheral
Neuropathy (RRPN, NINDS R24 NS098523), which was able
to generate multiple mouse models of human disease in any given
year at the scale of a single lab and modest funding. The KOMP2
phenotyping pipeline was established to capture data for gene
knockouts for the entire mammalian genome, and is
(intentionally) broad and not deep for any speciﬁc
physiological system (Brown et al., 2018). A given phenotype
domain, such as neuromuscular performance, may be covered by
only one or two tests, and is not supported by detailed physiology,
histology, or biomarker analysis. Therefore, high-throughput
pipelines such as KOMP2 are best suited for establishing
baseline data to describe gene function, and as discovery tools
to identify and prioritize disease-relevant mutant phenotypes for
more extensive analysis. The output from the program has been
signiﬁcant. For example, data from the International Mouse
Phenotyping Consortium (IMPC), to which KOMP2
contributes, has revealed that ∼40% of all lines generated have
phenotypic overlap with human disease and that for a signiﬁcant
majority, the IMPC model was the ﬁrst mutant mouse line
reported for the gene-disease (Meehan et al., 2017). IMPC
data has been mined to identify novel disease-relevant
phenotype associations for deafness, metabolic disease, and
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Provided the cell types of interest have established differentiation
protocols, experiments can largely be done using high-content
imaging platforms and automated morphometry and related
assays. Similarly-omics studies are highly feasible in such models.
Additional assays, such as mitochondrial function, organelle
trafﬁcking, etc. can also be done with reasonable throughput. Cell
lines do not necessarily have to recapitulate the disease to be useful.
For example, if iPSCs engineered to carry GARS/CMT2D mutations
show ISR activation when differentiated to motor neurons, this will
be a useful model even if they do not show axon degeneration.
However, this requires sufﬁcient understanding of the disease
mechanism to accurately interpret these secondary phenotypes.
Ultimately, gaining that level of understanding may require an in
vivo model, which may again limit the scale of these studies.
Nonetheless, the cell-based models may identify mechanisms to
be tested in vivo, improving efﬁciency, and once such mechanisms
are identiﬁed, the cell-based systems provide an efﬁcient platform for
testing interventions. Approaches such as transcriptomics or
biomarker analysis may also provide ways to readily bridge cellbased models with in vivo results and predictions.
An example of the successful use of an iPSC-based platform to
interrogate disease mechanism with the goal of bringing a
therapeutic to the clinic was done using cell-based models of
amyotrophic lateral sclerosis (ALS). Patient iPSC-derived motor
neurons with a disease-causing mutation in superoxide dismutase
1 (SOD1) were found to exhibit hyperexcitability. This was
similar to ﬁndings from clinical neurophysiological studies
(Wainger et al., 2014). This phenotype was abolished when
the SOD1 mutation was reversed in the cells using CRISPR
genome editing (Kiskinis et al., 2014). In addition, it was
found that the hyperexcitability was conserved across multiple
forms of ALS using iPSC-derived motor neurons from patients
with mutations in C9ORF72, FUS, and different SOD1 alleles
(Wainger et al., 2014). The hyperexcitability was successfully
corrected and motor neuron survival increased when treated with
the drug ezogabine (also known as retigabine), a Kv7.2/3
potassium channel agonist used to treat epilepsy (Wainger
et al., 2014). Data from these studies led to a recently
published double-blind, placebo-controlled phase 2 clinical
trial using ezogabine to reduce motor neuron hyperexcitability
in both familial and sporadic ALS patients. Notably, this drug was
not tested in the canonical SOD1 transgenic mouse model of ALS
before moving to clinical trials, as the human cell-based data was
deemed sufﬁcient (Mcneish et al., 2015; Wainger et al., 2021).

disease-causing gene, potential therapeutics can be properly
aligned with speciﬁc mutations. Phenotyping of these mouse
models can also be strategically prioritized by matching
prominent clinical features of the patients with a battery of
tests in mice that would zero in on these deﬁciencies. The
creation of these mini-pipelines allows for a ﬁrst pass, direct
interrogation of translationally relevant preclinical phenotypes
that can be rapidly evaluated with speciﬁc therapeutics. Keeping
in mind that ultimately, not every clinical feature in a patient may
be addressable. The goal of many therapeutics is not curative but
is to alleviate some of the features with the goal of improving the
quality of life for patients.
Approaches for achieving this are being piloted by programs
such as the JAX Center for Precision Genetics. This NIH-funded
program seeks to better integrate current efforts in human
genetics, disease modeling both in mice and in other systems,
and preclinical studies to lessen the time from gene discovery to
clinical trial. An important part of this effort is bioinformatics, to
evaluate the feasibility/necessity for making a model and for
optimizing the probability that such a model will be successful.
For example, if a disease mechanism or relevant biological
pathway is known, are some strains of inbred mice more or
less likely to be good genetic backgrounds for producing valid
disease models based on known differences in those pathways
across mouse strains? As described above, the genome
engineering capacity, although ultimately ﬁnite, is unlikely to
be limiting. Instead, the phenotyping capacity for validation of
disease models, as well as evaluating preclinical studies are still the
most labor intensive and time-consuming phase. It is not making
the model that is the challenge in 2021, it is proving it is a valid
model and using it productively that takes time and effort.

SUMMARY
We have provided an example of a rare neuromuscular disease,
inherited peripheral neuropathy caused by dominant tRNA
synthetase mutations, as a demonstration of how mouse and
human cell-based models can be integrated to understand disease
mechanisms, test therapeutic approaches, and improve the
likelihood of successful translation to clinical practice. Both in
vivo models such as mice and human cell-based models have
advantages and limitations. Relying on either alone has risks, so
the clear solution is to incorporate both approaches and thus
hopefully minimize those risks. For each, the challenge currently
is not genetically engineering the model, it is the effort of
validating the model as disease-relevant and using it in welldesigned preclinical studies. This is being successfully done for
many diseases besides inherited peripheral neuropathies, but it
remains a challenge to do it at a scale that will rapidly deliver
results for the ∼7,000 rare diseases now identiﬁed.

ADDRESSING SCALABILITY
While the challenges of creating, validating and using disease
models at scale are signiﬁcant, they are at least somewhat
addressable. CRISPR/Cas9 technology allows for the rapid
creation of patient-based mutations in mice. Mutations in any
one disease gene can be strategically prioritized based on criteria,
such as common mutations based on founder affects or
mutations that may be more amenable to genomic based
therapeutic strategies, such as ASOs, read through drugs, or
gene therapy. By creating an allelic series for a particular
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